Clinical Trials Logo

Metabolic Disease clinical trials

View clinical trials related to Metabolic Disease.

Filter by:

NCT ID: NCT05174104 Completed - Sleep Disorder Clinical Trials

Metabolic and Chronobiological Changes in Vestibular Rehabilitation

Start date: March 1, 2020
Phase: N/A
Study type: Interventional

The aim of the present study is to evaluate the impact of vestibular rehabilitation on metabolic aspects when evaluated by means of bioelectrical impedenzometry analysis, smart watch device and actigraphy in a group of vestibular hypofunction patients previously studied by means of video head impulse test, posturography and clinical validated scales

NCT ID: NCT05137990 Completed - Clinical trials for Overweight and Obesity

The HIIT Cognition Study

Start date: March 1, 2021
Phase: N/A
Study type: Interventional

This pilot study is a randomized control trial to test the effects of a 14-week home-based virtual, interactive high intensity interval training (HIIT) exercise intervention on cardiometabolic and cognitive outcomes in sedentary youth with overweight/obesity during adolescence. All participants (N=24) will complete screening via phone to determine eligibility. Eligible participants will be randomized to receive a) 14 weeks of a home-based HIIT intervention delivered via iPad or b) 14 weeks of a stretching intervention (control group). Each participant will undergo an in-lab pre- and post-test visit, where they will complete a fasting blood draw, a fitness test, and various cognitive and mental health measures.

NCT ID: NCT04854603 Completed - Clinical trials for Overweight and Obesity

Dairy Products With Reduced Sugar and Blood Glucose

Start date: September 2, 2021
Phase: N/A
Study type: Interventional

Dairy products represent an important food group in human nutrition as a source of calcium, protein, functional fats and low-glycaemic sugar lactose. While traditionally consumed natural milk and yogurt have low sugar content, many flavoured liquid dairy products such as chocolate milk, or fermented products such as yogurt have added sugar. Our recent studies have shown that the partial reduction of added sugar in chocolate milk and yogurt is not associated with any inferior sensory characteristics such as taste and pleasantness compared to their full-sugar counterparts. The current project will investigate whether the liquid dairy products with reduced sugar content (value-added products) have any benefits on blood glucose control in humans.

NCT ID: NCT04809220 Completed - Clinical trials for Diabetes Mellitus, Type 2

A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes

AWARD-JPN
Start date: April 13, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of 2 doses of dulaglutide in Japanese participants with type 2 diabetes. The study duration is approximately 58 weeks.

NCT ID: NCT04807959 Completed - Obesity Clinical Trials

Evaluation of the Effectiveness of a Comprehensive Visceral Adiposity-Focused Anti-Obesity Program

Start date: October 27, 2016
Phase:
Study type: Observational

A retrospective review of body composition outcomes of participants of a comprehensive visceral-fat focused anti-obesity program. Data from approximately 2000-2500 participants are expected to be included in the study.

NCT ID: NCT04804319 Completed - Metabolic Disease Clinical Trials

Interactions Between Diet, Microbiome and Abiotic Conditions in the Gut

PRIMA
Start date: April 13, 2021
Phase:
Study type: Observational

The aim of this study is to explore the interplay between environmental (abiotic) factors in the gut and the gut microbiota composition, diversity and metabolism. Such insights could help us understand personal responses to diets and be a first step towards personalized dietary recommendations targeting the gut microbiome.

NCT ID: NCT04663139 Completed - Obesity Clinical Trials

Xla1 Christensenella Minuta, Phase I, Randomized, Partially Placebo-controlled Double-blind Protocol, Evaluating Safety, Tolerability and Impact on the Gut Microbiota in Healthy Volunteers, Overweight and Obese Adults

CAUSALITY
Start date: November 1, 2020
Phase: Phase 1
Study type: Interventional

Xla1 Christensenella minuta, phase I, randomized, placebo-controlled double-blind protocol, evaluating safety, tolerability and impact on the gut microbiota in healthy volunteers, overweight and obese adults. This study is designed as a FIH, Phase I, daily oral single dose, clinical trial evaluating safety, tolerability and the impact on the gut microbiota following introduction of Xla1 performed in 2 parts: - Part 1: An open phase in normal weight healthy volunteers (HV) receiving all Xla1. - Part 2: A randomized, parallel, double-blind, placebo-controlled phase in overweight or obese (stage 1) adult patients receiving either Xla1 or placebo.

NCT ID: NCT04662411 Completed - Metabolic Disease Clinical Trials

Butyrate/Hexanoate in Metabolic Health

Start date: January 13, 2021
Phase: N/A
Study type: Interventional

In this study, we aim to identify a well consumable butyrate/hexanoate-enriched oil that increases circulating SCFA concentrations and improves postprandial substrate metabolism, which could be further used for a long-term study.

NCT ID: NCT04659902 Completed - Metabolic Disease Clinical Trials

Protein, Calcium and Gut Hormone Secretion

PROCAL2
Start date: December 1, 2020
Phase: N/A
Study type: Interventional

Hormones that are produced by our stomach and intestines play a role in regulating our appetite and health, and are therefore of high interest for managing conditions such as obesity and Type 2 Diabetes (T2D). Two important hormones, called GLP-1 and PYY, are released from the same intestinal cell. The food we eat influences the release of these hormone and evidence suggests that protein and calcium are key nutrients that stimulate the secretion of GLP-1, while the influence of this combination on PYY release is less clear. Furthermore, gastric emptying affects the rate of absorption of nutrients and by manipulating the structural form of protein, in the absence or presence of calcium, we may be able to learn more about the processes mediating the gut hormone response. We hypothesise that gut hormone secretion will be enhanced following the ingestion of a partially digested protein in the presence of calcium versus a control protein without calcium. Additionally, the ingestion of the partially digested protein will result in faster gastric emptying compared to the control protein.

NCT ID: NCT04613700 Completed - Obesity Clinical Trials

The Role of Secretin on the Energy Homeostasis

THE-ROSE
Start date: March 1, 2020
Phase: N/A
Study type: Interventional

As of last year, new insight into the function of secretin was brought about as rodent studies showed secretin to possess potential body weight-regulating effects. In these studies, secretin was shown to increase non-shivering thermogenesis in brown adipose tissue (BAT), decrease meal size and promote meal discontinuation. The mechanisms behind these regulatory effect of secretin on energy homeostasis are unclear,